Abstract Preterm infants are a special group, and related severe neurological, respiratory, and digestive disorders have high disability/fatality rates. Allogeneic cell transplantation may be an effective method for the prevention and treatment of these diseases. At present, animal studies have been conducted for allogeneic cell transplantation in the treatment of hypoxic-ischemic encephalopathy, bronchopulmonary dysplasia, and necrotizing enterocolitis. The main difficulty of this technique is graft-versus-host reaction (GVHR), and successful induction of immune tolerance needs to be achieved in order to solve this problem. This article reviews the research advances in immune tolerance of allogeneic cell transplantation in preterm infants.
Chang YS, Ahn SY, Sung S, et al. Stem cell therapy for neonatal disorders:prospects and challenges[J]. Yonsei Med J, 2017, 58(2):266-271.
[2]
Sharma AA, Jen R, Butler A, et al. The developing human preterm neonatal immune system:a case for more research in this area[J]. Clin lmmunol, 2012, 145(1):61-68.
[3]
赵勇. 移植免疫耐受[M]. 北京:中国医药科技出版社, 2005:191-200.
[4]
Yang S, Fujikado N, Kolodin D, et al. Immune tolerance.Regulatory T cells generated early in life play a distinct role in maintaining self-tolerance[J]. Science, 2015, 348(6234):589-594.
[5]
Zeng H, Zhang R, Jin B, et al. Type 1 regulatory T cells:a new mechanism of peripheral immune tolerance[J]. Cell Mol Immunol, 2015, 12(5):566-571.
[6]
Hippen KI, Riley JL, June CH, et al. Clinical perspective for regulatory T cells in transplantation tolerance[J]. Semin Immunol, 2011, 23(6):462-468.
[7]
Sakaguchi S, Yamaguchi T, Nomura T, et al. Regulatory T cells and immune tolerance[J]. Cell, 2008, 133(5):775-787.
[8]
Sharma AA, Jen R, Butler A, et al. The developing human preterm neonatal immune system:a case for more research in this area[J]. Clin lmmunol, 2012, 145(1):61-68.
[9]
Palmeira P, Quinello C, Silveira-Lessa AL, et al. IgG placental transfer in healthy and pathological pregnancies[J]. Clin Dev Immunol, 2012, 2012:985646.
[10]
Ohl K, Tenbrock K. Regulatory T-cells in systemic lupus erythematosus. IL-2 is decisive for loss of tolerance[J]. Z Rheumatol, 2016, 75(3):253-264.
[11]
He X, Koenen HJ, Slaats JH, et al. Stabilizing human regulatory T cells for tolerance inducing immunotherapy[J]. Immunotherapy, 2017, 9(9):735-751.
[12]
Le Poole IC, Mehrotra S. Replenishing regulatory T cells to halt depigmentation in vitiligo[J]. J Investig Dermatol Symp Proc, 2017, 18(2):38.
[13]
Pang N, Duan X, Jiang M, et al. Reconstitution and clinical significance of T cell subsets in the early stage after related HLA-mismatched peripheral blood hematopoietic SCT without T-cell depletion in vitro[J]. Int J Clin Exp Pathol, 2015, 8(8):8892-8901.
[14]
Mangus CW, Massey PR, Fowler DH, et al. Rapamycin resistant murine Th9 cells have a stable in vivo phenotype and inhibit graft-versus-host reactivity[J]. PLoS One, 2013, 8(8):e72305.
[15]
Pang N, Xu J, Qu J, et al. Peripheral blood Th9 cells reconstitution and its relationship with acute graft-versus-host disease after matched-sibling peripheral blood hematopoietic stem cell transplantation[J]. Am J Transl Res, 2017, 9(8):3623-3632.
[16]
Audiger C, Rahman MJ, Yun TJ, et al. The importance of dendritic cells in maintaining immune tolerance[J]. J Immunol, 2017, 198(6):2223-2231.
[17]
Idoyaga J, Fiorese C, Zbytnuik L, et al. Specialized role of migratory dendritic cells in peripheral tolerance induction[J]. J Clin Invest, 2013, 123(2):844-854.
[18]
Horton C, Shanmugarajah K, Fairchild PJ. Harnessing the properties of dendritic cells in the pursuit of immunological tolerance[J]. Biomed J, 2017, 40(2):80-93.
[19]
Chen L, Zheng L, He W, et al. Cotransfection with IL-10 and TGF-β1 into immature dendritic cells enhances immune tolerance in a rat liver transplantation model[J]. Am J Physiol Gastrointest Liver Physiol, 2014, 306(7):G575.
[20]
Zhou J, He W, Luo G, et al. Mixed lympfocyte reaction induced by mutiple alloantigens and the role for IL-10 in prolifertion inhibition[J]. Burns Trauma, 2014, 2(1):24-28.
[21]
Chinen T, Kannan AK, Levine AG, et al. An essential role for the IL-2 receptor in Treg cell function[J]. Nature Immunol, 2016, 17(11):1322-1333.
[22]
Wolf D, Barreras H, Bader CS, et al. Marked in vivo donor Treg expansion via IL-2 and TL-Ig stimulation ameliorates GVHD but preserves GVL in recipients post-HSCT[J]. Biol Blood Marrow Transplant, 2017, 23(5):757-766.
[23]
Brandenburg S, Takahashi T, de la Rosa M, et al. IL-2 induces in vivo suppression by CD4(+)CD25(+)Foxp3(+) regulatory T cells[J]. Eur J Immunol, 2008, 38(6):1643-1653.
[24]
Qiu M, Chen Y, Chen L, et al. Transforming growth factor β1 and Fas ligand synergistically enhance immune tolerance in dendritic cells in liver transplantation[J]. J Surg Res, 2017, 218(9):180-193.
[25]
Ilstad ST, Sachs DH. Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts[J]. Nature, 1984, 307(5947):168-170.
[26]
Alpdogan O, van den Brink MR. Immune tolerance and transplantation[J]. Semin Oncol, 2012, 39(6):629-642.
[27]
Im KI, Park MJ, Kim N, et al. Induction of mixed chimerism using combinatory cell-based immune modulation with mesenchymal stem cells and regulatory T cells for solid-organ transplant tolerance[J]. Stem Cell Dev, 2014, 23(19):2364-2376.
[28]
Mattar CN, Biswas A, Choolani M, et al. The case for intrauterine stem cell transplantation[J]. Best Pract Res Clin Obstet Gynaecol, 2012, 26(5):683-695.
[29]
Nemeth K. Mesenchymal stem cell therapy for immune-modulation:the donor, the recipient, and the drugs in-between[J]. Exp Dermatol, 2014, 23(9):625-628.
[30]
Li A, Jiang J, Zhang Q, et al. Cytokines transduced bone marrow stromal cell lines promote immunohematopoietic reconstitution in mice after allogeneic bone marrow transplantation[J]. Immounol Let, 2005, 98(2):216-224.
[31]
Cencioni MT, Santini S, Ruocco G, et al. Fas-ligand regulates differential activation-induced cell death of human T-helper 1 and 17 cells in healthy donors and multiple sclerosis patients[J]. Cell Death Dis, 2015, 6:e1785.
[32]
Collette Y, Benziane A, Razanajaoua D, et al. Distinct regulation of T-cell death by CD28 depending on both its aggregation and T-cell receptor triggering:a role for Fas-FasL[J]. Blood, 2013, 92(4):1350-1363.